CLYM Q4 2025 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena

CLYMClimb Bio, Inc.

$522M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$30,000

Operating Income

-$19M

Net Income

-$18M

EPS (Diluted)

$-0.26

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$168M

Total Liabilities

$7M

Stockholders' Equity

$160M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$30,000	$0	—
Operating Income	-$19M	-$11M	-76.8%
Net Income	-$18M	-$8M	-108.1%